ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-OR046

The Influence of Microbiome Composition on the Development and Progression of IgA Nephropathy

Session Information

Category: Glomerular Diseases

  • 1202 Glomerular Diseases: Immunology and Inflammation


  • Nakhoul, Farid M., Baruch Padeh Poriya Medical Ctr., Lower Galilee, Israel
  • Evgeny, Farber, Baruch Padeh Poriya Medical Ctr., Lower Galilee, Israel
  • Koren, Omri, Azrieli Faculty of Medicine, Tzfat, Israel
  • Bathish, Younes, Nephrology Division, Ezfat, Israel
  • Hnut, Anaam, Baruch Padeh Poriya Med Ctr, Lower Galilee, Israel
  • Zellner, Ido, Azrieli Faculty of Medicine, Tzfat, Israel
  • Tehawkho, Sophia, Baruch Padeh Poriya Med Ctr, Lower Galilee, Israel
  • Dahan, Inbal, Diabetes &Metabolism Lab, Lower Galilee, Israel

IgA Nephropathy (IgAN) is an auto-immune dis., characterized by abnormal deposition of IgA1 antibody with aberrant O-glycosylation in the glomerular mesangium, resulting in local inflammation. Aberrantly glycosylated IgA1 may be synthesized in response to a mucosal infection and may include deregulated innate immune responses. IgAN usually characterized with variability in its manifestation between different patients. The human microbiome is involved in normal host physiology & several metabolic diseases. It was shown that IgAN patients had an altered fecal microbiota, but the exact relationship between microbiome composition and IgAN is still understood.


Stool sample from 26 IgAN patients and 26 healthy control individuals subjected to microbiome array and to taxonomic analysis, to characterize their microbiome compositions. Creatinine, albumin and urine proteinuria levels are used for evaluate the renal function of each IgAN patient. The clinical and laboratory evaluations will be crossed with the taxonomic data using statistical analysis.


Preliminary result with 11 IgAN patients and 11 healthy controls , there are significant differences in the microbiome composition between the two groups. IgAN patients have a significant increase in the Bacteroides phylum accompanied with a significant decrease in the amount of both the Actinobacteria and Verrucomicrobia phyla, compared with the healthy individuals (Fig.1). At the genus level, there is a significant increase in the Prevotella bacteria in the IgAN subjects compared with the healthy individuals.


1. A strong association between specific bacteria population and IgAN
2. To isolate specific population of bacteria that leads to IgAN or even aggravate its manifestation.
3. Develop disease-specific therapies based on microbiome modulations and manipulations by modifying the gut microbiota through diet, antibiotic Tx, probiotic interventions, fecal transplants.